A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure

Exclusion Criteria

• •patients with passes through the digestive tract disorders
• •patients with uncontrolled constipation symptoms
• •kidney transplant patients
• •patients who are taking immunosuppressive drugs
• •patients suffering from digestive tract ulcers and esophageal varices
• •patients with uncontrolled hypertension
• •patients hospitalized with cardiovascular disease within 3 months of the screening
• •patients with current infections
• •patients who do not fulfill therapies of chronic renal failure (taking medicine and diet) as appropriate
• •patients with hepatic impairment (2.5 times greater than the upper limit of normal levels of AST, ALT)
• •uncontrolled diabetes (HbA1c \> 10 % or a fasting glucose \> 180mg / dL)
• •patients with malignant tumors (However, if you do not relapse within five years after completion of therapy can be registered)
• •pregnant women, nursing mothers
• •those who do not agree to a contraceptive method allowed for the possibility of pregnancy in women
• •patients participating in another clinical trial in addition to the current clinical trial
• •subjects with dependency on drugs or alcohol
• •subjects who took any other investigational drugs within 30 days before participating this clinical trial study
• •patients expected to starting the dialysis within three months
• •other patients deemed unsuitable tester